Jim Simons Imara Inc. Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$3.73 - $5.2 $430,904 - $600,724	-115,524 Reduced 35.08%	213,800 $874,000
Q3 2022 Nov 14, 2022	SELL	$1.11 - $2.42 $86,797 - $189,234	-78,196 Reduced 19.19%	329,324 $751,000
Q2 2022 Aug 12, 2022	SELL	$0.99 - $1.87 $42,550 - $80,372	-42,980 Reduced 9.54%	407,520 $497,000
Q1 2022 May 13, 2022	BUY	$1.15 - $2.41 $12,534 - $26,269	10,900 Added 2.48%	450,500 $847,000
Q4 2021 Feb 11, 2022	BUY	$2.25 - $4.05 $371,925 - $669,465	165,300 Added 60.26%	439,600 $989,000
Q3 2021 Nov 12, 2021	BUY	$4.08 - $7.83 $956,890 - $1.84 Million	234,532 Added 589.75%	274,300 $1.12 Million
Q2 2021 Aug 13, 2021	BUY	$6.78 - $9.04 $269,627 - $359,502	39,768 New	39,768 $314,000
Q4 2020 Feb 10, 2021	SELL	$15.81 - $29.0 $193,277 - $354,525	-12,225 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$18.75 - $28.58 $14,325 - $21,835	-764 Reduced 5.88%	12,225 $249,000
Q2 2020 Aug 13, 2020	BUY	$15.6 - $54.87 $202,628 - $712,706	12,989 New	12,989 $359,000

104K

170K

Ticker IMRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,287,300
Market Cap $552M
Description
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develop...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.